MedTrace Logo

Testosterone Treatment in Men With Chronic Kidney Disease

NCT05249634 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-30

No results posted yet for this study

Summary

This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).

Conditions

  • Hypogonadism, Male
  • Kidney Disease, Chronic

Interventions

DRUG

Jatenzo Pill

oral tablet daily

Sponsors & Collaborators

  • Clarus Therapeutics, Inc.

    collaborator INDUSTRY

  • St. Louis University

    lead OTHER

Principal Investigators

  • Sandeep Dhindsa, MD · St. Louis University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2028-06-30
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05249634 on ClinicalTrials.gov